Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Tang Capital Management LLC

Tang Capital Management LLC decreased its position in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 65.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,641,945 shares of the biopharmaceutical company’s stock after selling 3,058,055 shares during the quarter. Tang Capital Management LLC owned 2.97% of Marinus Pharmaceuticals worth $879,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Beryl Capital Management LLC acquired a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth about $2,262,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth about $54,000. XTX Topco Ltd lifted its holdings in shares of Marinus Pharmaceuticals by 1,564.7% during the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 206,614 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Marinus Pharmaceuticals by 266.1% during the fourth quarter. JPMorgan Chase & Co. now owns 487,584 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 354,393 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth about $36,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Marinus Pharmaceuticals in a report on Tuesday, May 13th. They set a “sell” rating for the company. One analyst has rated the stock with a sell rating, seven have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Trading Down 0.2%

Shares of MRNS stock opened at $0.55 on Monday. The stock has a 50 day moving average of $0.55 and a 200 day moving average of $0.48. The stock has a market cap of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals, Inc. has a twelve month low of $0.22 and a twelve month high of $1.97.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.